Branchial Clefts with Characteristic Facies, Growth Retardation, Imperforate (Blocked) Nasolacrimal Duct, and Premature Ageing

Branchio-Oculo-Facial Syndrome (BOFS) (also called Braddock-Carey syndrome/Braddock syndrome). It is a rare genetic condition caused by TFAP2A gene variants and characterized by branchial cleft anomalies, characteristic facial features, growth delay, nasolacrimal duct obstruction/imperforation, ocular anomalies, and sometimes a premature-aging (progeroid) appearance.

Branchio-oculo-facial syndrome is a rare condition present from birth. It affects the skin and tissues of the neck (branchial clefts), the eyes and tear-drainage system (oculo), and the shape of the face (facial). Children can have small pits, cysts, or sinuses in the side of the neck (branchial cleft anomalies), blocked tear ducts (imperforate nasolacrimal duct), cleft lip/palate or high-arched palate, wide-spaced eyes, and distinctive nose and jaw shape. Many have feeding and speech issues, eye surface irritation from poor tear drainage, and a higher risk of infections in neck cysts. The syndrome is autosomal dominant and most often caused by variants in the TFAP2A gene, which controls early embryo development of the face, eyes, and ears. NCBI+2MedlinePlus+2

BOFS is a congenital (present at birth) condition that alters how the branchial arches form the face, neck, ears, and related structures. Typical signs include distinctive facial features, skin and sinus tracts from branchial clefts, eye/tear-duct abnormalities (often blocked nasolacrimal ducts), and occasionally slow growth. The look of “premature ageing” in some infants is a progeroid facies—thin or tight skin and characteristic facial contours—rather than true early ageing of the whole body. Genetic Rare Diseases Info Center+2MedlinePlus+2

The TFAP2A gene encodes transcription factor AP-2α. This protein helps switch on other genes at the right time in the embryo. When TFAP2A does not work normally, tissues that form the eye, ear, face, body wall and tear ducts can develop abnormally. That is why babies can be born with blocked tear ducts, branchial pits or cysts, cleft lip/palate, and other facial differences. The link between TFAP2A and these tissues has been shown in human genetics and animal studies, and TFAP2A variants causing BOFS have been confirmed in multiple families. NCBI+1

Another names

This condition has been reported under several descriptive or historical names in medical sources. Using these names can help you find the same disorder in different references:

• Branchio-oculo-facial syndrome (BOFS). This is the most widely used, current name. Genetic Rare Diseases Info Center+1

• Branchial clefts with characteristic facies, growth retardation, and imperforate nasolacrimal duct (a descriptive label that highlights the most visible features and is used by some rare-disease registries). checkorphan.org

• Branchiooculofacial disorder (spelled as one word in some databases). UniProt+1

Note: “Braddock syndrome/Braddock-Carey syndrome” is a different, very rare malformation condition with a VACTERL-like pattern; it is not the same as BOFS even though online search results can appear nearby. NCBI+1

Types

Doctors do not use formal “types” for BOFS the way they do for some other syndromes, but in practice people often fit into patterns like these:

1. Classic BOFS. Clear branchial-cleft sinuses/skin changes behind the ears or on the neck, distinctive facial features (broad or prominent nasal bridge, long or narrow philtrum of the upper lip, sometimes a lip “pseudocleft”), and eye involvement such as a blocked tear duct. Growth may be small for age. MedlinePlus+2UniProt+2

2. Eye-predominant BOFS. Tear-duct blockage and other ocular findings stand out (e.g., small eyes, surface defects), while branchial skin tracts are subtle. MedlinePlus+1

3. Skin/branchial-predominant BOFS. Linear skin lesions and branchial cleft pits or sinuses dominate, with milder eye changes. MedlinePlus

4. Mild/attenuated BOFS. Features are present but subtle; a parent may have only a small skin pit or a history of tear-duct probing, and the child shows the full picture. This can reflect variable expression with the same TFAP2A change. MedlinePlus

Causes

Think of “causes” here as the different biologic and clinical reasons a child can present with the BOFS picture or individual parts of it:

1. Pathogenic variants in TFAP2A (AP-2α). This is the principal cause of BOFS; the gene controls many steps in branchial arch development. MedlinePlus

2. Autosomal-dominant inheritance. A parent with a subtle form can pass the variant to a child who is more affected (variable expressivity). MedlinePlus

3. De novo (new) variant. Most children have a brand-new TFAP2A change not found in either parent. Genetic Rare Diseases Info Center

4. Parental germline mosaicism. A parent can carry the change in a fraction of egg/sperm cells with minimal signs, leading to recurrence in siblings. (General mechanism recognized across dominant genetic disorders.) MedlinePlus

5. Developmental errors of branchial clefts. These produce pits, sinuses, or cysts in the neck/ear region. NCBI

6. Abnormal craniofacial patterning. TFAP2A variants disrupt early facial “blueprints,” causing characteristic facies. MedlinePlus

7. Abnormal tear-duct canalization. A persistent membrane at the valve of Hasner can block the nasolacrimal duct at birth. Pediatric Oncall

8. Prematurity as a contributor to tear-duct blockage. Preterm birth increases the chance of congenital nasolacrimal duct obstruction. PubMed

9. Secondary acquired nasolacrimal obstruction (later in life). Infection, inflammation, trauma, or drugs can block tear ducts (not BOFS-specific but can coexist). eyewiki.org

10. Gene-environment interactions. In some genetic syndromes, background genes or exposures modify severity; this likely contributes to variable BOFS features. MedlinePlus

11. Abnormal skin/vascular development near branchial areas. Hemangiomatous or scarred skin behind the ears and lower neck is typical. checkorphan.org

12. Ear-structure malformations tied to branchial arch development. Posteriorly angulated pinnae, pits, or unusual helices can occur. checkorphan.org

13. Nasal/philtral morphogenesis changes. A long, narrow philtrum or pseudocleft reflects how midface tissues joined in early development. checkorphan.org+1

14. Ocular surface anomalies. Small corneas/eyes or surface defects may be part of the syndrome in some people. MedlinePlus

15. Cleft lip and/or palate association. A subset have lip or palate clefts, consistent with branchial arch involvement. UniProt

16. Feeding difficulties and poor weight gain. Structural differences and reflux can contribute to growth issues. (Phenotype descriptions note low birthweight/slow growth.) monarchinitiative.org

17. Recurrent infections of branchial sinuses. Draining tracts can become infected, worsening scarring. NCBI

18. Airway anomalies (less common). Midface and palate differences can influence breathing during sleep or anesthesia assessments. (Craniofacial sources note peri-anesthetic considerations.) accessanesthesiology.mhmedical.com

19. Hearing pathway differences. Middle/outer ear anomalies can impair hearing in some patients. MedlinePlus

20. Dental enamel and jaw alignment differences. Reported in some cohorts of BOFS and similar craniofacial disorders, contributing to feeding/speech issues. malacards.org

Symptoms

Not everyone has every feature. Severity can vary—even inside one family.

1. Small size at birth and slow growth. Many babies are smaller than expected and grow at a slower pace in childhood. Genetic Rare Diseases Info Center+1

2. Blocked tear ducts (constant tearing). Tears overflow (epiphora), often noted in the first weeks of life. malacards.org+1

3. Recurrent eye discharge or infections. Because tears do not drain, sticky discharge and conjunctivitis are common. Pediatric Oncall

4. Distinctive facial look. Broad nasal bridge, narrow/long philtrum, and other characteristic features make up the BOFS facies. MedlinePlus

5. Skin lines or pits behind the ears/neck. These reflect branchial sinus tracts or healed hemangiomatous areas. checkorphan.org

6. Small or unusual ears; ear pits. External-ear shape can be different. checkorphan.org

7. Cleft lip and/or palate (in some). This can affect feeding and speech. UniProt

8. Hoarse cry, nasal voice, or feeding difficulties. Structure differences can affect airway and swallowing. accessanesthesiology.mhmedical.com

9. Hearing loss (variable). Conductive loss may occur with external/middle-ear anomalies. MedlinePlus

10. Dry or fragile skin in involved areas. Atrophic or scarred skin patches are described. accessanesthesiology.mhmedical.com

11. Dental differences. Enamel defects or malocclusion may be noted as teeth erupt. malacards.org

12. Frequent nasal congestion or mouth breathing. Midface and palate differences can narrow airflow. accessanesthesiology.mhmedical.com

13. Neck swelling or drainage from a small opening. A sign of an infected branchial sinus/cyst. NCBI

14. Eye surface irritation. Poor tear drainage or eye shape changes can dry or irritate the surface. MedlinePlus

15. Appearance of “premature ageing” (progeroid facies). Some infants’ facial soft tissues and skin create an aged look, although systemic ageing is not occurring. checkorphan.org

Diagnostic tests

A) Physical examination (bedside observation)

1. Full craniofacial exam. The clinician looks for the distinctive facies, ear shape, philtrum, nasal bridge, and any lip/palate cleft. This exam guides further testing. MedlinePlus

2. Skin and neck inspection. Linear lesions or tiny openings behind the ears or on the neck suggest a branchial sinus. checkorphan.org

3. Eye exam with dye or light. Basic checks for tearing, redness, and discharge can point to a blocked tear duct. Pediatric Oncall

4. Growth measurements over time. Height/weight/head size are plotted to confirm growth delay. Genetic Rare Diseases Info Center

5. Oro-nasal and palate exam. Detects cleft or submucous cleft and guides feeding and speech plans. UniProt

B) Manual/office procedures

1. Lacrimal sac (tear-duct) massage test. Gentle massage over the tear sac can express mucus/tears and help confirm obstruction; it is also a first-line therapy in infants. Pediatric Oncall
2. Fluorescein dye disappearance test. A tiny drop of dye is placed in the eye; persistent dye after 5 minutes supports blocked outflow. Pediatric Oncall
3. Probing and irrigation of the nasolacrimal duct. In an ophthalmology office, a fine probe passes into the duct to confirm and treat the blockage. Pediatric Oncall
4. Otoscopic exam and pneumatic otoscopy. Checks ear canals, eardrum mobility, and middle-ear status related to hearing. MedlinePlus
5. Audiology screening (otoacoustic emissions in clinic). A quick newborn/infant screen that prompts full testing if abnormal. MedlinePlus

C) Laboratory and pathological tests

1. Genetic testing of TFAP2A. Sequencing and deletion/duplication analysis confirm BOFS and support family counseling. Genetic Rare Diseases Info Center+1
2. Targeted gene panel for craniofacial/branchial syndromes. Useful when the picture is not classic; panels include TFAP2A and related genes. MedlinePlus
3. Wound/skin culture if a branchial sinus is infected. Guides antibiotics when drainage or cellulitis occurs. NCBI
4. Basic labs for growth concerns (as needed). Nutritional and endocrine screens look for treatable contributors to poor growth alongside structural issues. (General pediatric practice.) Genetic Rare Diseases Info Center

D) Electrodiagnostic tests

1. Auditory brainstem response (ABR). An objective test that measures how the hearing nerve and brainstem respond to sound—important if ear structure is atypical. MedlinePlus
2. Visual electrophysiology (when indicated). Electroretinography or visual evoked potentials can clarify ocular involvement if vision seems reduced. MedlinePlus

E) Imaging tests

1. Neck ultrasound. Shows a cystic tract or fluid collection from a branchial cleft and helps plan surgery if needed. NCBI
2. CT or MRI of the neck and temporal bone. Maps a complex branchial sinus or ear malformation and its relation to nerves and vessels before an operation. NCBI
3. Dacryocystography or dacryoscintigraphy (special tear-duct imaging). Confirms the site of lacrimal blockage when surgery is being considered. Pediatric Oncall
4. 3-D craniofacial imaging (as needed). Helps orthodontic or surgical teams visualize jaw, palate, and airway relationships. (Used selectively in syndromic craniofacial care.) accessanesthesiology.mhmedical.com

Non-pharmacological treatments (therapies and other measures)

Note: To keep this readable, I’ve written each item as a short, clear paragraph with Purpose and Mechanism included. These are standard supportive measures used for BOFS features (branchial clefts, lacrimal obstruction, cleft-related issues, growth delay, and ocular surface disease). Evidence comes from BOFS overviews and condition-specific guidelines (branchial clefts, CNLDO). NCBI+2NCBI+2

1. Early genetics consultation and family counseling.
   Description (≈150 words): A clinical geneticist confirms the diagnosis, arranges TFAP2A testing, reviews recurrence risk (autosomal dominant), screens for associated features (ear, eye, dental, palate, and hearing), and coordinates care with ENT, ophthalmology, dentistry, speech therapy, and craniofacial team. Clear counseling reduces uncertainty and supports family planning.
   Purpose: Confirm diagnosis; plan surveillance and referrals; inform family risk.
   Mechanism: Identifies pathogenic TFAP2A variant; triggers tailored, multidisciplinary care pathways. NCBI

2. Multidisciplinary craniofacial team care.
   Description: Coordinated care by ENT, ophthalmology, plastic/craniofacial surgery, dentistry/orthodontics, speech therapy, audiology, and nutrition addresses the multiple body systems affected at the right age/stage.
   Purpose: Optimize growth, feeding, speech, eye protection, and airway/dentition.
   Mechanism: Team scheduling aligns surgeries (e.g., cleft repair with ear tubes) and therapies to minimize anesthesia events and improve outcomes. NCBI

3. Lacrimal sac massage (Crigler technique) and lid hygiene in infancy.
   Description: For congenital nasolacrimal duct obstruction (NLDO), caregivers gently massage the lacrimal sac several times daily and keep eyelids clean. Many cases resolve without procedures in the first 6–12 months.
   Purpose: Promote duct opening, reduce discharge/infection.
   Mechanism: Pressure transiently increases hydrostatic force, helping open the membranous block at the valve of Hasner; hygiene reduces bacterial load. NCBI+1

4. Ocular surface protection (artificial tears/ointments; moisture shields).
   Description: Tears or ointment reduce irritation from poor drainage; moisture shields at night protect the cornea.
   Purpose: Prevent keratitis and corneal damage from tear stasis or exposure.
   Mechanism: Lubricants stabilize the tear film; shields reduce evaporation and friction. rarediseases.org

5. Speech-language therapy (pre- and post-cleft repair).
   Description: Early therapy improves feeding strategies and later articulation/resonance after cleft palate/lip repair.
   Purpose: Improve communication, feeding safety, and growth.
   Mechanism: Targeted oral-motor and resonance exercises enhance velopharyngeal function. NCBI

6. Feeding and nutrition support.
   Description: Lactation support, specialized bottles, thickened feeds (if advised), and dietitian input help infants with cleft-related feeding difficulty and growth delay.
   Purpose: Achieve adequate growth and micronutrient intake.
   Mechanism: Practical adaptations reduce nasal regurgitation and fatigue; nutrition plans meet energy needs. NCBI

7. Hearing evaluation and early intervention.
   Description: Regular audiology checks and timely ear-tube placement if indicated reduce speech/language delays.
   Purpose: Protect hearing-dependent development.
   Mechanism: Treats middle-ear effusion from Eustachian dysfunction associated with craniofacial anomalies. NCBI

8. Dental/orthodontic care.
   Description: BOFS can include dental anomalies and malocclusion. Early dental care, fluoride, and later orthodontics improve chewing, hygiene, and look.
   Purpose: Preserve teeth and function; prepare for orthognathic plans if needed.
   Mechanism: Caries prevention plus staged orthodontics aligns arches and improves occlusion. NCBI

9. Skin/neck sinus care and infection prevention.
   Description: Keep branchial pits and sinus openings clean and dry; prompt evaluation at signs of infection (redness, swelling, fever).
   Purpose: Reduce recurrent infections while awaiting definitive surgery.
   Mechanism: Hygiene lowers bacterial colonization and maceration risk. NCBI

10. Sun protection and gentle skincare for “premature-aging” look.
    Description: Broad-spectrum sunscreen, hats, and moisturizers help protect fragile-appearing skin if a progeroid appearance is present.
    Purpose: Limit photoaging and skin breakdown.
    Mechanism: UV avoidance reduces collagen damage; emollients support barrier function. DermNet®

11. Developmental surveillance and early childhood intervention.
    Description: Routine screening for motor, language, and cognitive milestones with referral to local early-intervention services when needed.
    Purpose: Catch delays early and support school readiness.
    Mechanism: Structured therapy improves neurodevelopmental outcomes. NCBI

12. Psychosocial support for child and family.
    Description: Counseling and peer support groups reduce stress around visible differences, surgeries, and school issues.
    Purpose: Improve quality of life and adherence to care.
    Mechanism: Coping skills and social support reduce anxiety/depression and improve engagement with treatment. NCBI

13. Airway and sleep assessment if craniofacial structure suggests risk.
    Description: Evaluate snoring, obstructive symptoms, or feeding-related breathing issues; sleep study if indicated.
    Purpose: Prevent growth and learning impacts of sleep-disordered breathing.
    Mechanism: Identifies obstruction amenable to ENT interventions. NCBI

14. Prophylactic eye-surface care during respiratory infections.
    Description: Extra lid hygiene and lubricant use during colds when tear drainage worsens.
    Purpose: Reduce conjunctivitis risk.
    Mechanism: Lowers microbial load and mechanical irritation. NCBI

15. Timing strategy for lacrimal procedures.
    Description: Observe through infancy if safe; proceed to probing after 6–12 months if persistent, and to intubation or balloon dilation if probing fails. DCR is reserved for older children.
    Purpose: Maximize spontaneous resolution while preventing ongoing infections.
    Mechanism: Step-up approach balances natural history with risks of chronic obstruction. PMC+1

16. Pre-surgical infection control (neck lesions).
    Description: Treat acute infection first, then plan excision when inflammation is quiet to lower recurrence and complications.
    Purpose: Safer surgery and better healing.
    Mechanism: Active infection increases scarring and fistula persistence; controlling it improves outcomes. NCBI+1

17. Cleft lip/palate surgical pathway and peri-operative therapy.
    Description: Standard cleft protocols: lip repair in infancy, palate repair in the first year, with coordinated speech and ENT care.
    Purpose: Improve feeding, speech, hearing, and appearance.
    Mechanism: Restores anatomic continuity and velopharyngeal function. NCBI

18. Eye protection education for caregivers.
    Description: Teach signs of corneal irritation (pain, light sensitivity, redness) and hygiene steps; stress urgency if symptoms appear.
    Purpose: Prevent corneal ulcers/scarring.
    Mechanism: Rapid response to symptoms reduces complications of tear stasis. rarediseases.org

19. Routine vaccinations and general pediatric care.
    Description: Keep immunizations up to date; coordinate around surgical dates when possible.
    Purpose: Prevent avoidable infections that could worsen ENT/eye issues.
    Mechanism: Active immunity reduces common respiratory/ocular infections. NCBI

20. Transition-to-adulthood planning.
    Description: Prepare adolescents for self-management, dental/orthodontic completion, and long-term ophthalmology/ENT follow-up.
    Purpose: Maintain vision, hearing, oral health, and psychosocial wellbeing.
    Mechanism: Structured handover prevents care gaps. NCBI

---

Drug treatments

There is no single disease-specific drug for BOFS; medications are used to treat infections, protect the ocular surface, and manage pain/fever. Below are commonly used, FDA-labeled agents for bacterial eye/ENT infections or supportive care. Doses are examples (adults unless noted); always individualize with a clinician, especially for infants/children.

1. Moxifloxacin ophthalmic 0.5% (Vigamox / Moxeza).
   Class: Fluoroquinolone antibiotic (topical ophthalmic). Typical dosage: 1 drop in affected eye(s) 3×/day for 7 days (per product label; pediatric dosing varies). Time: Start at diagnosis of bacterial conjunctivitis or post-procedure per doctor. Purpose: Treat bacterial eye infections complicating NLDO or after lacrimal procedures. Mechanism: Inhibits bacterial DNA gyrase/topoisomerase IV. Side effects: Eye irritation, dysgeusia; hypersensitivity is rare. FDA Access Data+1

2. Ofloxacin ophthalmic 0.3% (Ocuflox).
   Class: Fluoroquinolone antibiotic. Dosage: 1–2 drops every 2–4 hours for 2 days, then 4×/day up to 7 days (per label). Purpose/Mechanism: As above—broad ocular antibacterial coverage by inhibiting DNA gyrase. Side effects: Transient burning, stinging. FDA Access Data+1

3. Levofloxacin ophthalmic (IQUIX/QUIXIN).
   Class: Fluoroquinolone. Dosage: Label-guided (e.g., IQUIX 1.5% dosing for corneal ulcers differs from 0.5% solutions). Purpose: Treat susceptible ocular infections. Mechanism: Inhibits bacterial DNA replication. Side effects: Eye irritation, bitter taste. FDA Access Data+2FDA Access Data+2

4. Polymyxin B/Trimethoprim ophthalmic (Polytrim).
   Class: Combination antibacterial (cell-membrane disruption + folate-pathway inhibition). Dosage: 1 drop every 3 hours (max 6×/day) for 7–10 days per label. Purpose: First-line option for pediatric bacterial conjunctivitis. Side effects: Local irritation; hypersensitivity. FDA Access Data+1

5. Tobramycin ophthalmic 0.3% (Tobrex).
   Class: Aminoglycoside antibiotic. Dosage: 1–2 drops every 4 hours (more frequent in severe cases) per label. Purpose: Treat external ocular infections. Mechanism: Blocks bacterial protein synthesis (30S). Side effects: Local irritation; rare allergy. FDA Access Data

6. Amoxicillin-clavulanate (Augmentin).
   Class: β-lactam + β-lactamase inhibitor (oral). Dosage: Common adult dose 875/125 mg q12h with food; pediatric weight-based dosing per label. Purpose: Treat acute infections of branchial cleft cysts/sinuses and surrounding tissues when culture suggests susceptible organisms. Mechanism: Inhibits cell-wall synthesis and β-lactamase. Side effects: GI upset, rash; rare hepatotoxicity. Antibiotic stewardship applies. FDA Access Data

7. Acetaminophen (paracetamol).
   Class: Analgesic/antipyretic. Dosage: Adults often 325–1,000 mg per dose (max per label), pediatric weight-based; avoid overdose. Purpose: Pain/fever relief after ENT/ocular procedures. Mechanism: Central COX modulation. Side effects: Liver toxicity with overdose or chronic high dosing. FDA Access Data

8. Topical antibiotic ointment for peri-incisional skin (per surgeon).
   Class: Various (e.g., erythromycin ophthalmic for eyelid margin as instructed). Dosage: Thin ribbon to incision/eyelid margin per surgeon’s regimen. Purpose: Reduce superficial infection risk after lacrimal procedures. Mechanism: Local antibacterial action. Side effects: Local irritation; hypersensitivity. (Regulatory note: ophthalmic erythromycin has historic FDA approvals via DESI and is commonly used for neonatal prophylaxis.) FDA Access Data

9. Post-operative steroid/antibiotic eye drops (as prescribed).
   Class: Combination products; exact label varies. Dosage: Taper per surgeon. Purpose: Control inflammation and infection risk after ocular procedures. Mechanism: Anti-inflammatory corticosteroid plus antibacterial. Side effects: IOP rise (steroids), irritation. (Use only under ophthalmologist guidance.) FDA Access Data

10. Saline nasal/ocular irrigation (non-drug medical device/OTC).
    Class: Isotonic saline preparations. Dosage: As directed. Purpose: Aid hygiene around tear puncta and nose after procedures; reduce crusting. Mechanism: Mechanical debris removal and moisture support. Side effects: Minimal if sterile technique used. (General supportive measure; not an FDA-approved “drug.”) PMC

If you want, I can add 10 more FDA-sourced drug write-ups (e.g., other ophthalmic antibacterials) in a second batch—just say “more drugs.”

---

Dietary molecular supplements

These do not treat the genetic cause. They support eye surface health, wound healing, and general growth. Always review supplements with your clinician—especially for infants/children.

1. Omega-3 fatty acids (DHA/EPA).
   Dose (adult typical): 1–2 g/day combined EPA+DHA (adjust pediatrics with clinician). Function: Supports meibomian gland function and tear film stability. Mechanism: Anti-inflammatory lipid mediators improve tear quality and reduce evaporative loss. PMC

2. Vitamin A (within RDA).
   Dose: Meet but do not exceed age-appropriate RDA. Function: Maintains corneal/Conjunctival epithelial health. Mechanism: Retinoids regulate epithelial differentiation and mucin expression. (Excess can be toxic—medical guidance needed.) PMC

3. Vitamin D (correct deficiency).
   Dose: Physician-guided to correct measured deficiency. Function: Immune modulation and bone growth. Mechanism: Nuclear receptor signaling influences innate/adaptive immunity and bone mineralization. NCBI

4. Vitamin C.
   Dose: RDA-level supplementation. Function: Collagen synthesis for wound healing (cleft/ENT surgeries). Mechanism: Cofactor for prolyl/lysyl hydroxylases in collagen maturation. NCBI

5. Zinc.
   Dose: RDA range only. Function: Epithelial repair and immune function. Mechanism: Enzyme cofactor in DNA synthesis and antioxidant defense. NCBI

6. Probiotics (clinician-selected strains).
   Dose: Per product; avoid in immunocompromised hosts without advice. Function: GI support during/after antibiotics for infected branchial lesions. Mechanism: Microbiome modulation may reduce antibiotic-associated diarrhea. FDA Access Data

7. Lutein/Zeaxanthin (age-appropriate).
   Function: Antioxidant carotenoids for retinal/ocular surface health. Mechanism: Quenches oxidative stress in ocular tissues. rarediseases.org

8. Evening primrose oil (GLA).
   Function: May support tear film lipid layer in some dry-eye phenotypes. Mechanism: Omega-6 derivatives modulate inflammatory pathways affecting meibum quality. PMC

9. Protein-adequate diet (medical nutrition).
   Function: Supports growth and post-operative healing. Mechanism: Provides amino acids for collagen and immune proteins. NCBI

10. Iron (if deficient) under medical supervision.
    Function: Correct anemia that can worsen fatigue and growth. Mechanism: Restores hemoglobin and tissue oxygen delivery. NCBI

---

Immunity-booster / regenerative / stem-cell–related drugs

There is no approved stem-cell drug for BOFS. Below are context-appropriate notes on immune support and tissue healing frequently used in pediatric ENT/ophthalmic care. These are not BOFS-specific cures.

1. Vaccines (routine schedule).
   Dose: Per national program. Function/Mechanism: Trains adaptive immunity; reduces respiratory/ocular infection burden that can worsen ENT/eye problems. NCBI

2. Post-operative topical steroids (short course if prescribed).
   Function: Control inflammation after ocular/ENT surgery to promote healing. Mechanism: Glucocorticoid receptor-mediated cytokine suppression. (Prescription only; monitor IOP in eyes.) FDA Access Data

3. Autologous serum tears (specialist-directed).
   Function: For severe ocular surface disease not relieved by lubricants. Mechanism: Patient’s serum growth factors promote epithelial healing. (Off-label; specialist care.) rarediseases.org

4. Topical cyclosporine A for dry-eye phenotypes (specialist).
   Function: Improves tear production in inflammatory dry eye. Mechanism: Calcineurin inhibition reduces T-cell–mediated inflammation. (Prescription; not for acute infection.) rarediseases.org

5. Nutritional repletion (iron, vitamin D) when deficient.
   Function: Optimizes immune and tissue repair capacity. Mechanism: Corrects deficiency-related immune dysfunction. NCBI

6. Hematopoietic/mesenchymal stem-cell therapy
   Function: Not indicated for BOFS; mentioned only to clarify there is no evidence-based role. Mechanism: N/A. (Avoid unproven “stem-cell” offers.) NCBI

---

Surgeries

1. Excision of branchial cleft cyst/sinus/tract.
   Procedure: After any infection is controlled, a surgeon removes the entire cyst and tract through a neck incision, sometimes in stepladder fashion.
   Why: Prevents recurrent infections, drainage, and rare complications. NCBI+1

2. Nasolacrimal duct probing.
   Procedure: A probe opens the membrane at the distal duct under anesthesia in infants/young children when obstruction persists.
   Why: Restores tear drainage; reduces discharge/infections. PMC

3. Silicone intubation or balloon dacryoplasty.
   Procedure: A soft stent is passed through the duct (intubation) or a balloon catheter dilates the duct if probing fails.
   Why: Keeps the tract open to allow healing and flow. ijceo.org

4. External or endoscopic dacryocystorhinostomy (DCR).
   Procedure: Creates a new tear-drainage opening between sac and nasal cavity in older children/adults with resistant obstruction.
   Why: Bypasses a blocked duct to stop tearing/infections. ijceo.org

5. Cleft lip/palate repair (with possible ear tubes).
   Procedure: Standard staged craniofacial surgeries in infancy/early childhood; may combine with tympanostomy tubes.
   Why: Improve feeding, speech, hearing, and facial function. NCBI

---

Preventions

1. Keep eyelids clean and use lacrimal massage in infancy as taught by your clinician to reduce stagnation and infection. NCBI

2. See ophthalmology early if discharge/redness persists or vision concerns arise. Early care prevents corneal damage. PMC

3. Treat neck pit/cyst infections promptly; avoid squeezing or probing at home. NCBI

4. Schedule definitive branchial cleft excision when infection is quiet to prevent recurrence. childrenshospital.org

5. Follow a step-up plan (observe → probe → intubate/balloon → DCR) for persistent tear-duct blockage. PMC+1

6. Keep vaccines up to date to reduce respiratory infections that can worsen eye discharge. NCBI

7. Maintain regular dental and orthodontic care to prevent caries and support jaw development. NCBI

8. Use sun protection and gentle skin care, especially if skin looks thin or aged. DermNet®

9. Attend speech-language therapy early if cleft palate or resonance issues are present. NCBI

10. Keep follow-up with the craniofacial team; coordinated care reduces complications over time. NCBI

---

When to see doctors (red-flag list)

See a doctor immediately for any of the following: eye pain, light sensitivity, decreased vision, or corneal-ulcer symptoms; fever, spreading redness, or swelling around a neck pit/cyst; persistent purulent eye discharge despite hygiene; breathing or feeding problems in infants; recurrent ear infections or suspected hearing loss; poor weight gain; speech delay; or social/learning issues that might need extra support. Early specialty referral (ophthalmology, ENT, craniofacial, speech therapy, genetics) improves outcomes and prevents long-term complications. NCBI+2NCBI+2

---

What to eat” and “what to avoid

Eat more of:

1. Protein-rich foods (eggs, fish, legumes) for healing and growth, especially around surgery. NCBI
2. Fruits/vegetables for vitamin C and antioxidants that support tissue repair. NCBI
3. Foods with healthy fats (fish, nuts) for omega-3s that support tear film stability. PMC
4. Dairy or fortified alternatives for calcium/vitamin D if tolerated. NCBI
5. Adequate fluids to keep mucosa and tear film hydrated. PMC

Limit/avoid:

1. Sugary drinks/snacks that displace nutrients needed for growth. NCBI
2. Highly salty/processed foods before surgery (can worsen swelling/irritation). NCBI
3. Excess vitamin A supplements (risk of toxicity); stay within RDA unless prescribed. NCBI
4. Allergens/personal triggers that worsen eye rubbing/nasal irritation. rarediseases.org
5. Unregulated “stem-cell” or miracle cures marketed as dietary products. NCBI

---

Frequently Asked Questions

1. Is there a cure?
   No single medicine cures BOFS. Care focuses on fixing specific problems (blocked tear ducts, neck cysts, cleft lip/palate) and protecting vision, hearing, speech, and growth. Genetic counseling explains inheritance and testing. NCBI

2. Is it inherited?
   BOFS is usually autosomal dominant. A parent with the variant has a 50% chance to pass it to a child, but many cases are new (de novo). NCBI

3. What gene is involved?
   TFAP2A. It controls other genes during early development of the face, eye, ear, and related tissues. NCBI

4. Do blocked tear ducts always need surgery?
   No. Many infant obstructions open naturally; persistent cases may need probing, intubation, or DCR based on age and severity. PMC

5. Are branchial cleft cysts dangerous?
   They commonly get infected and drain. The usual plan is antibiotics for infection, then complete surgical removal to prevent recurrence. NCBI

6. What causes the ‘premature-aging’ look?
   Some people with BOFS have a progeroid facial appearance—likely from the same developmental changes that alter facial tissues. It is a described but variable feature. PMC+1

7. Will my child need many surgeries?
   It depends on features present (cleft lip/palate, tear-duct obstruction, branchial cysts). Craniofacial teams plan and coordinate to reduce repeated anesthesia. NCBI

8. Can BOFS affect hearing or speech?
   Yes—ear problems and cleft palate can impact both; early audiology and speech-language therapy help. NCBI

9. Do eye antibiotics fix tear-duct obstruction?
   No. They treat infection, not the blockage. Mechanical procedures restore drainage when needed. FDA Access Data+1

10. Is genetic testing useful?
    Yes. Finding a TFAP2A variant confirms diagnosis and guides family counseling. NCBI

11. Can diet or vitamins cure BOFS?
    No. Nutrition supports growth and healing, but it does not change the gene. Avoid megadoses without medical advice. NCBI

12. Are there long-term risks to the eyes?
    Risk comes from chronic tearing and infections causing corneal irritation. Regular ophthalmic care prevents damage. rarediseases.org

13. What is the outlook?
    With coordinated care, most children do well—growing, learning, and participating fully, though they may need staged procedures and therapies. NCBI

14. How common is infant tear-duct blockage in general?
    Even in healthy infants, 6–20% have congenital NLDO, and most resolve in year one. In BOFS, persistence can be higher and needs closer follow-up. NCBI+1

15. Where can I read more?
    See GeneReviews (comprehensive clinical overview), MedlinePlus Genetics, and peer-reviewed case reports. NCBI+2MedlinePlus+2

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 02, 2025.